# A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

> **NCT03496974** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 38 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Bermekimab Monoclonal Antibody 200 mg
- **DRUG:** Bermekimab Monoclonal Antibody 400 mg

## Key facts

- **NCT ID:** NCT03496974
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2018-12-04
- **Final completion:** 2018-12-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496974, "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03496974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*